When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response

doi:10.3748/wjg.v20.i23.7207

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 23

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5756)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

392

WORD

228

HTML

3508

Tables (1-2)

198

Sum=4326

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

829

Download

601

Sum=1430

Jun 21, 2014 (publication date) through Jun 15, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 21, 2014; 20(23): 7207-7212
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7207

Table 1 Criteria for stopping nucleos(t)ide analogue therapy in chronic hepatitis B patients

	HBeAg-positive chronic hepatitis B	HBeAg-negative chronic hepatitis B
APASL 2012	HBeAg seroconversion with undetectable HBV DNA for at least 12 mo	HBsAg seroclearance or NA therapy > 2 yr and undetectable HBV DNA on three separate occasions, 6 mo apart
EASL 2012	HBsAg seroclearance or HBeAg seroconversion with undetectable HBV DNA and 12 mo of consolidation therapy	HBsAg seroclearance
AASLD 2009	HBeAg seroconversion with undetectable HBV DNA and > 6 mo of consolidation therapy	HBsAg seroclearance

HBeAg: Hepatitis Be antigen; APASL: Asian Pacific Association for the Study of the Liver; EASL: European Association for the Study of Liver; AASLD: American Association of the Study of Liver Disease.

Citation: Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212
URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7207.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7207